Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Regeneron Pharmaceuticals ... Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of China for HS-20094 (a dual GLP-1/GIP receptor agonist ...

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced an in-licensing agreement with Hansoh Pharmaceuticals to acquire clinical ... provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist.

Credit: lev radin/Shutterstock. Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094. The agreement will involve the ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

The acquisition of HS-20094 enhances Regeneron’s portfolio of obesity and metabolic programs, which aim to improve the quality of weight loss and address long-term health comorbidities.

Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline ... This novel therapeutic candidate (HS-20094) – studied in over 1,000 patients and administered ...

Key complementary asset enables synergy and flexibility across Regeneron's broad pipeline of obesity and ... This novel therapeutic candidate (HS-20094) - studied in over 1,000 patients and ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Additionally, Regeneron has entered into a licensing agreement with Hansoh Pharmaceuticals for the obesity drug candidate HS-20094, with an upfront payment of $80 million and potential future ...